4.5 Article

Natural history of Barth syndrome: a national cohort study of 22 patients

Journal

ORPHANET JOURNAL OF RARE DISEASES
Volume 8, Issue -, Pages -

Publisher

BMC
DOI: 10.1186/1750-1172-8-70

Keywords

Barth syndrome; Cardiomyopathy; Neutropenia; TAZ gene; Cohort

Funding

  1. Amgen SAS
  2. Chugai SA
  3. GIS Maladies Rares
  4. Institut de Veille Sanitaire
  5. Inserm
  6. Societe d'Hemato Immunologie Pediatrique et La Societe Francaise de Cardiologie Pediatrique
  7. Barth France Association

Ask authors/readers for more resources

Background: This study describes the natural history of Barth syndrome (BTHS). Methods: The medical records of all patients with BTHS living in France were identified in multiple sources and reviewed. Results: We identified 16 BTHS pedigrees that included 22 patients. TAZ mutations were observed in 15 pedigrees. The estimated incidence of BTHS was 1.5 cases per million births (95% CI: 0.2-2.3). The median age at presentation was 3.1 weeks (range, 0-1.4 years), and the median age at last follow-up was 4.75 years (range, 3-15 years). Eleven patients died at a median age of 5.1 months; 9 deaths were related to cardiomyopathy and 2 to sepsis. The 5-year survival rate was 51%, and no deaths were observed in patients >= 3 years. Fourteen patients presented with cardiomyopathy, and cardiomyopathy was documented in 20 during follow-up. Left ventricular systolic function was very poor during the first year of life and tended to normalize over time. Nineteen patients had neutropenia. Metabolic investigations revealed inconstant moderate 3-methylglutaconic aciduria and plasma arginine levels that were reduced or in the low-normal range. Survival correlated with two prognostic factors: severe neutropenia at diagnosis (<0.5 x 10(9)/L) and birth year. Specifically, the survival rate was 70% for patients born after 2000 and 20% for those born before 2000. Conclusions: This survey found that BTHS outcome was affected by cardiac events and by a risk of infection that was related to neutropenia. Modern management of heart failure and prevention of infection in infancy may improve the survival of patients with BTHS without the need for heart transplantation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available